7.87

0.25% 0.02

Regulus Therapeutics Inc (RGLS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$7.85

Aprire:

$7.85

Volume 24 ore:

860.01K

Relative Volume:

0.48

Capitalizzazione di mercato:

$544.84M

Reddito:

Utile/perdita netta:

$-30.04M

Rapporto P/E:

-4.981

EPS:

-1.58

Flusso di cassa netto:

$-27.38M

1 W Prestazione:

+0.00%

1M Prestazione:

+305.67%

6M Prestazione:

+450.35%

1 anno Prestazione:

+293.50%

Intervallo 1D:

$7.84

$7.88

Intervallo di 1 settimana:

$7.82

$7.9001

Portata 52W:

$0.8301

$8.20

Regulus Therapeutics Inc Stock (RGLS) Company Profile

Nome

Regulus Therapeutics Inc

Settore

Healthcare (1170)

Industria

Biotechnology (671)

Telefono

858-202-6300

Indirizzo

4224 CAMPUS POINT COURT, SAN DIEGO, CA

Dipendente

Cinguettio

@regulusrx

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

RGLS's Discussions on Twitter

Confronta RGLS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RGLS Regulus Therapeutics Inc	7.87	544.87M	0	-30.04M	-27.38M	-1.58
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-03-27	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2024-08-02	Iniziato	Oppenheimer	Outperform
2024-03-18	Iniziato	Leerink Partners	Outperform
2018-03-28	Iniziato	B. Riley FBR, Inc.	Neutral
2018-01-05	Iniziato	Leerink Partners	Outperform
2017-06-13	Reiterato	Chardan Capital Markets	Buy
2017-03-06	Reiterato	Wedbush	Outperform
2017-01-30	Downgrade	Needham	Buy → Hold
2017-01-30	Downgrade	Wells Fargo	Outperform → Market Perform
2016-12-07	Reiterato	Chardan Capital Markets	Buy
2016-11-02	Reiterato	Needham	Buy
2016-07-25	Reiterato	Chardan Capital Markets	Buy
2016-06-28	Reiterato	Chardan Capital Markets	Buy
2016-06-28	Reiterato	FBR Capital	Outperform
2016-06-28	Reiterato	Needham	Buy
2016-06-07	Reiterato	Chardan Capital Markets	Buy
2016-04-13	Iniziato	Chardan Capital Markets	Buy
2015-12-04	Iniziato	Wells Fargo	Outperform
2015-06-09	Iniziato	Guggenheim	Buy
2015-04-21	Ripresa	FBR Capital	Outperform
2014-11-24	Iniziato	Deutsche Bank	Buy
2014-08-07	Reiterato	FBR Capital	Outperform
2013-08-14	Reiterato	Needham	Buy

Mostra tutto

Regulus Therapeutics Inc Borsa (RGLS) Ultime notizie

May 15, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - GlobeNewswire Inc.

May 15, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

May 15, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView

May 15, 2025

May 14, 2025

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors - The Globe and Mail

May 14, 2025

May 09, 2025

Regulus Therapeutics to be Acquired by Novartis - TipRanks

May 09, 2025

May 08, 2025

Regulus: Q1 Earnings Snapshot - Norwalk Hour

May 08, 2025

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - StreetInsider

May 08, 2025

Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway - GuruFocus

May 08, 2025

May 06, 2025

Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN

May 06, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com

May 06, 2025

May 04, 2025

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire

May 04, 2025

May 03, 2025

Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus

May 03, 2025

Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN

May 03, 2025

May 02, 2025

Taxation With Representation: Goodwin, Haynes Boone - Law360

May 02, 2025

Regulus (RGLS) Sees Increased Put Trading Activity | RGLS Stock News - GuruFocus

May 02, 2025

May 01, 2025

Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - San Diego Union-Tribune

May 01, 2025

Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus

May 01, 2025

This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga

May 01, 2025

New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com

May 01, 2025

Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare

May 01, 2025

Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com

May 01, 2025

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN

May 01, 2025

Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers

May 01, 2025

Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus

May 01, 2025

Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billio - GuruFocus

May 01, 2025

Apr 30, 2025

Regulus (RGLS) Downgraded After Acquisition Agreement with Novar - GuruFocus

Apr 30, 2025